

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 October 2019 (03.10.2019)



(10) International Publication Number
WO 2019/191773 A1

(51) International Patent Classification:

A61K 31/122 (2006.01) A23L 33/15 (2016.01)
A61K 31/593 (2006.01) A23L 33/155 (2016.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2019/025220

(22) International Filing Date:

01 April 2019 (01.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/650,674 30 March 2018 (30.03.2018) US
62/816,499 11 March 2019 (11.03.2019) US

(71) Applicant: **KAYDENCE PHARMA AS** [NO/NO]; Lil-leakerveien 2B, 2083 Oslo (NO).

(72) Inventors: **CHLOPICKI, Stefan**; Bobrzynskiego 14, 30-348 Krakow (PL). **MARESZ, Katarzyna**; c/o International Science and Health Foundation, Kunickiego st. 10, 30-134 Krakow (PL).

(74) Agent: **BERMAN, Richard J.** et al.; Arent Fox, LLP, 1717 K Street, N.W., Washington, District of Columbia 20006-5344 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: RAPIDLY IMPROVING VASCULAR CONDITIONS BY ADMINISTERING VITAMIN K

(57) Abstract: A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. The vitamin K can be administered together with additional substances such as vitamin D.



WO 2019/191773 A1

RAPIDLY IMPROVING VASCULAR CONDITIONS BY ADMINISTERING VITAMIN K

Field of the Invention

[0001] The present invention is directed to the administration of vitamin K to quickly improve vascular conditions, such as endothelial function, reduce arterial stiffness, and reverse calcification of blood vessels in mammals in less than six months, preferably less than 6 weeks. The present invention is also directed to the administration of vitamin K to increase endothelial nitric oxide production in mammals.

Background of the Invention

[0002] The process of aging in mammals is associated with irreversible physiological changes to the circulatory system, leading to an increased risk of blood pressure disorders, Coronary Heart Disease (CHD) and stroke. For women, this risk rises dramatically after the onset of menopause. These conditions have a significant impact on quality of life for the middle-aged and elderly and account for a large proportion of deaths and chronic illnesses in modern societies.

[0003] Patients suffering from cardiovascular disorders are frequently prescribed anticoagulants, anti-hypertensives, cholesterol lowering medications, and other medications. These medications usually present harmful side-effects or health risks and moreover, the chronic effects of taking such medications regularly over the course of years or decades are not well understood. As life expectancies increase, it would be desirable to find safe and reliable natural therapies to prevent, treat or even reverse the consequences of aging on the vasculature.

[0004] Changes in mechanical properties of the main arteries have major implications for the development of vascular disease. Blood vessels are made of three layers, the tunica intima, the tunica media and the tunica adventitia. Calcification can occur in or on any of these layers. Typically, calcification of the blood vessel makes the vessel wall rigid, fragile and subject to rupture. For purposes of the present invention, blood vessels include capillaries, veins, arteries, venules, and/or arterioles. Arteries, especially the larger elastic arteries such as the common carotid artery, become stiffer with age. Measures of large artery stiffening include compliance and distensibility. Compliance reflects the buffering capacity of the vascular vessel wall, and distensibility refers to the intrinsic vascular wall elasticity. In cross-sectional studies it has been shown that the distensibility and compliance of the elastic common carotid artery decrease linearly with age. The increase in arterial stiffness with increasing age is suggested to occur more rapidly in women aged between 45 and 60 years than in men of the same age group due to the lack of estrogen after menopause.

[0005] Reductions in compliance and distensibility result in an impairment of the arterial system to cushion pulsatile pressure. Arterial stiffening results in a higher pulse wave velocity and earlier wave reflections. This increases systolic and pulse pressure and consequently cardiac workload. To compensate, the arterial diameter increases with age. Over time, arterial stiffening can contribute to the development of, inter alia, left ventricular hypertrophy, congestive heart failure and coronary heart disease.

[0006] It has long been recognized that vitamin K is an essential component of the diet. It was first identified as an element needed to prevent hemorrhaging by activating blood-clotting factors. Natural K-vitamins are menadione-derivatives differing from each other in the polyisoprenoid side chain attached to the 3-position of the ring structure. Vitamin K can be provided in the diet by dark green, leafy vegetables (K1 or

phylloquinone), and by fermented foods such as cheese and curd (K2 or menaquinone). K2 vitamins are also synthesized in the small intestine by resident symbiotic bacteria. Vitamin K is also needed for carboxylation of two bone matrix proteins necessary for normal bone metabolism.

[0007] Example 1 of U.S. Application Serial No. 15/151,970, published as US 2016/0250160 (herein incorporated by reference), discloses that, after 3 years, the co-administration of Vitamin K and Vitamin D was effective in slowing and maybe even reversing the process of stiffening of the arteries, while the administration of Vitamin D alone was not. See paragraph [0080]. The preferred treatment time for limiting an increase in arterial stiffness is a minimum of 6 months, more preferably at least 12 or 18 months, and ideally at least 36 months. See paragraph [0045]. The application also discloses that vitamin K can be used to reduce or reverse calcification of a blood vessel. See paragraph [0054]. The preferred treatment period for removal of calcification can be a minimum of 6-12 weeks, preferably at least 6-8 months and most preferably at least 12 months or longer. See paragraph [0060].

[0008] EP-A-0 679 394 and Jpn. J. Pharmacol. (1997) 75: 135-143 disclose that a high dietary intake of vitamin K and related molecules can reduce further arterial calcification, but not reverse it, from which it is concluded that arteriosclerosis can be treated using vitamin K. Arteriosclerosis is a disease of the arteries characterized by inflammation, macrophage invasion, foam cell formation, intima thickening, accretion of cholesterol and formation of the atherosclerotic plaque, which over time can become calcified. The onset of atherosclerosis is invariably in the large arteries such as for example, the aorta and coronary arteries. In more advanced stages one may see plaque rupture leading to sudden vascular occlusion, myocardial infarction and cerebrovascular accident (infarction of the brain).

[0009] A completely different process is that of vascular stiffening due to loss of elasticity of the arteries. Vascular stiffening is associated with ageing, diabetes mellitus and renal dysfunction; it is the result of degradation of the elastic lamellae in the tunica media resulting in loss of elasticity. The onset of vascular stiffening is generally seen in the smaller vessels but extends to the large arteries. This will lead to increased blood pressure, vascular widening, and in later stages to rupture of mainly the small arteries and capillaries.

[0010] Studies have shown that on a molecular level, age-related stiffening of the arteries can be distinguished from arteriosclerotic/atherosclerotic calcification. Whereas atherosclerosis is invariably associated with inflammation and starts with destruction of the endothelium at the luminal side of the tunica intima, age-related stiffening is a process, which originates in the tunica media, and is not associated with inflammation. It is believed that age-related stiffening occurs as a result of deposition of minerals around the elastic fibers of the tunica media, followed by degradation of the elastin structure. After deterioration of the elastin, the elastic properties of the artery depend on collagen, which is much less flexible.

[0011] The endothelium is involved in most if not all disease states, either as a primary determinant of pathophysiology or as a victim of collateral damage (Chlopicki S. *Perspectives in pharmacology of endothelium: From bench to bedside*. Pharmacol Reports 2015;67:vi – ix; Frolow M, Drozd A, Kowalewska A, Nizankowski R, Chlopicki S. Comprehensive assessment of vascular health in patients; towards endothelium-guided therapy. Pharmacol Rep 2015;67:786–92). Endothelial dysfunction is associated with diseases/conditions including peripheral vascular disease, stroke, heart disease, diabetes, insulin resistance, chronic kidney failure, kidney transplants, tumor growth, metastasis, venous thrombosis, septic shock, hypertension, smoking, chronic exposure

to air pollution, physical inactivity cardiovascular disease, coronary artery disease, chronic heart failure, hemodialysis, kidney transplants, hyperparathyroidism, hyperphosphatemia and severe viral infectious diseases. Endothelial dysfunction is characterized by improper regulation of vascular tone due to an imbalance of vasodilating and vasoconstricting substances associated with vascular endothelial cells (e.g. low production/availability of nitric oxide or increased availability of endothelium derived contracting factors). Endothelial dysfunction can precede the development of atherosclerosis.

[0012] The endothelium lines the interior surface of all blood vessels and lymphatic vessels. Vascular endothelial cells form a single layer interface between circulating blood and the vessel wall. The endothelium has a central role in the regulation of blood flow through continuous modulation of vascular tone. This is primarily accomplished by balanced release of endothelial relaxing and contractile factors. Healthy endothelial cells are essential for the maintenance of vascular homeostasis. The vascular endothelium has several functions including acting as a barrier to control the passage of materials and white blood cells, fluid filtration, vasoconstriction and vasodilation (controlling blood pressure), and control of thrombosis and thrombolysis. Vascular endothelial cells prevent thrombosis by means of different anticoagulant and antiplatelet mechanisms. These cells are involved in hemostatic pathways triggered upon vascular injury and limit clot formation to the areas where hemostasis is needed to restore vascular integrity. Thus, vascular endothelial cells play a regulatory role in the circulation as a physical barrier and as a source of regulatory substances. Endothelial cells can produce and release nitric oxide and prostacyclin which are associated with vascular relaxation and inhibit platelet activation. Under specific conditions, endothelial cells can also release endothelium-derived contracting factors (EDCFs), including

endothelins, angiotensin II, thromboxane A2 cyclooxygenase-derived prostanoids and superoxide anions. Vascular endothelial cells are also a source of growth inhibitors and promoters and thus play a role in the regulation of vascular growth.

[0013] Clinical investigations regarding the improvement and/or complete reversal of endothelial dysfunction are constantly being undertaken. A pharmacological approach for improving/reversing endothelial dysfunction has been shown to be beneficial in clinical trials investigating the actions of different cardiovascular drugs (e.g. Rosuvastatin, Perindopril, Nebivolol, Carvedilol, Pioglitazone, Telmisartan, Gliclazide, Pitavastatin, Telmisartan, Atorvastatin, Lisinopril, Spironolactone, L-thyroxin, Infliximab, and Simvastatin). The finding of the effect of vitamin K on endothelial function indicates a novel therapeutic perspective for vitamin K as a vasoprotective agent in various diseases associated with endothelial dysfunction.

Summary of the Invention

[0014] The present invention provides for the use of vitamin K in the preparation of a pharmaceutical or nutritional formulation for improving cardiovascular function, elasticity, pulse wave velocity or endothelial dysfunction, reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal, wherein the improvement occurs in less than 6 months, preferably less than 6 weeks. The present invention also provides for the use of vitamin K in the preparation of a pharmaceutical or nutritional formulation for increasing endothelial nitric oxide production in a mammal.

[0015] Administration of vitamin K can lead to a rapid improvement in cardiovascular function, elasticity, pulse wave velocity or endothelial function, a rapid reduction in arterial stiffness and/or rapid removal of calcified precipitates from blood vessels that have already been affected by pre-existing calcification. Treatment with

vitamin K can rapidly reverse existing artery disease and reduce the risk of an incident requiring intense medical treatment. Though vitamin K was previously administered for improving arterial compliance and distensibility, it was believed that, in order for such improvement to occur, the vitamin K had to be administered for a minimum of 6 months, more preferably at least 12 or 18 months, and ideally at least 36 months. See US 2016/0250160.

[0016] In one aspect, the invention provides a method for improving cardiovascular function, elasticity, pulse wave velocity or endothelial dysfunction, reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal by administering vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in a medicament or nutritional formulation for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks.

[0017] In another aspect, the invention provides a method for treating age related stiffening of arteries, an age-related decrease in compliance and/or distensibility of arteries and/or an age-related increase in pulse pressure, comprising administering vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in a medicament or nutritional formulation for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months,

less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks.

[0018] In another aspect, the invention provides a method for reversing pre-existing calcification of blood vessels, comprising administering vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in a medicament or nutritional formulation for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-20 weeks or 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks. Calcification of a blood vessel can be associated with diseases/conditions such as arteriosclerosis including Monckeberg's sclerosis, osteoarthritis, inflammation-induced calcification, including Bechterev's disease, tumor-induced calcification, kidney (renal) transplants, hyperparathyroidism, hyperphosphatemia, skin calcification, including pseudo-xanthoma elasticum (PXE), chronic kidney disease (CKD), including Stage 1 CKD, Stage 2 CKD, Stage 3 CKD, Stage 4 CKD, and Stage 5 CKD, and calcifylaxis in end stage renal disease.

[0019] In another aspect, the invention provides a method for treating a disease/condition selected from arteriosclerosis such as Monckeberg's sclerosis, osteoarthritis, inflammation-induced calcification such as Bechterev's disease, tumor-induced calcification, kidney (renal) transplants, hyperparathyroidism, hyperphosphatemia, skin calcification such as pseudo-xanthoma elasticum (PXE), chronic kidney disease (CKD) such as Stage 1 CKD, Stage 2 CKD, Stage 3 CKD, Stage

4 CKD, and Stage 5 CKD, and calcifylaxis in end stage renal disease, comprising administering vitamin K or a derivative thereof, optionally together with vitamin D or a derivative thereof, in a medicament or nutritional formulation for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks.

[0020] In another aspect, the invention provides a method for increasing endothelial nitric oxide production in a subject, the method comprising administering vitamin K or a derivative thereof in a medicament or nutritional formulation to the subject. According to some aspects, the subject may either present with atherosclerotic plaques or may present without atherosclerotic plaques. According to some aspects, the subject may suffer from hypercholesterolemia. Treatment may be for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement in endothelial nitric oxide production occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks.

[0021] In a further aspect, the medicament or nutritional formulation can contain one or more additional components selected from: polyphenols, vitamin C, vitamin D, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty

acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12. The medicament or nutritional formulation can be administered simultaneously, separately or sequentially with a medicament selected from the group consisting of anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, anticanginals, hypolipidaemic agents, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics and calcium antagonists.

[0022] In another aspect of the invention, a composition is provided for improving cardiovascular function, elasticity, pulse wave velocity or endothelial dysfunction, reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal. The composition preferably contains 10 µg to 2000 mg of vitamin K, more preferably 100 µg to 50 mg, 200 µg to 20 mg, or 400 µg to 10 mg.

[0023] Additional features and advantages of various embodiments will be set forth in part in the description that follows and in part will be apparent from the description, or may be learned by practice of various embodiments. The objectives and other advantages of various embodiments will be realized and attained by means of the elements and combinations particularly pointed out in the description and appended claims.

Brief Description of the Drawings

[0024] FIG.1(A) –1(C) show the endothelium dependent response *in vivo* as assessed using MRI. (A); analysis of plaque size and composition by quantitative histologic evaluation (B); analysis of media thickness and vascular wall structure (C). A: 3D image of an aortic arch, with the following vessels: (1) brachiocephalic artery (BCA), (2) left common carotid artery (LCA) and (3) subclavian artery (LSA), acquired with the

cine IntraGate® FLASH 3D sequence. Endothelial function assessment was expressed as changes in the vessel's volume. B: Representative images of the BCA cross-sections stained with OMSB, showing atherosclerotic plaque (P) with lipid core (Lc) and collagen (C), artery lumen (L) and wall (W). Internal wall area (IWA) was determined as sum of plaque area and lumen area, while VWA is a media layer marked in red (W). C: Remodelling of vascular wall with increased media thickness associated with atherosclerosis development. Subsequent slices in the middle part of the BCA, showing vascular wall remodelling with visible increased thickness of smooth muscle vascular layers between elastic laminae - the histopathological basis of changes in VWA .

[0025] FIG. 2(A)- 2(B) show the effects of treatment with low and high doses of vitamin MK-7 on endothelial function *in vivo* in ApoE/LDLR^{-/-} mice. Changes in end-diastolic volume of a brachiocephalic artery (A: BCA) and left common carotid artery (B: LCA) 25 min after Ach administration in non-treated ApoE/LDLR^{-/-} mice (white columns) and in ApoE/LDLR^{-/-} mice treated with vitamin MK-7 given at the low (0.03 mg/kg b.w./day, black columns) or the high dose (10 mg/kg b.w./day, columns with diagonal lines) for two months (Untreated_6m: n=10, MK-7 [0.03 mg/kg]: n=8, MK-7 [10 mg/kg]: n=6). Statistics: one-way ANOVA (HSD Tukey's test); *p<0.05, **p<0.01 vs. Untreated_6m mice.

[0026] FIG. 3(A) -3(B) show the effects of treatment with low and high dose of vitamin MK-7 on nitrite (NO₂⁻) and nitrate (NO₃⁻) concentration in plasma in ApoE/LDLR^{-/-} mice. Changes in NO₂⁻ and NO₃⁻ concentration in plasma in non-treated ApoE/LDLR^{-/-} mice (white columns) and in ApoE/LDLR^{-/-} mice treated with vitamin MK-7 given at the low (0.03 mg/kg b.w./day, black columns) or high dose (10 mg/kg b.w./day, columns with diagonal lines) for two months (Untreated_6m: n=10, MK-7 [0.03 mg/kg]: n=9, MK-

7 [10 mg/kg]: n=10). Statistics: one-way ANOVA (HSD Tukey's test); *p<0.05, **p<0.01 vs. Untreated_6m mice, +p<0.05 for MK-7 [10 mg/kg] vs. MK-7 [0.03 mg/kg].

[0027] FIG. 4(A)-4(B) show the effects of treatment with low and high doses of vitamin MK-7 treatment on vessel wall structure and media thickness in ApoE/LDLR^{-/-} mice. Vessel wall area (A: VWA) of BCA in non-treated ApoE/LDLR^{-/-} mice (white columns) and in ApoE/LDLR^{-/-} mice treated with vitamin MK-7 in low (0.03 mg/kg b.w./day, black columns) and high dose (10 mg/kg b.w./day, columns with diagonal lines) for two months (Untreated_6m: n=6, MK-7 [0.03 mg/kg]: n=7, MK-7 [10 mg/kg]: n=6). The assessment was performed for entire vessel (A) and for divided vessel (B) in proximal, middle and distal parts. Statistics: Kruskal Wallis test; *p<0.05, **p<0.01, ***p<0.001 vs. Untreated_6m mice, +p<0.05, ++p<0.01 for MK-7 [10 mg/kg] vs. MK-7 [0.03 mg/kg].

[0028] FIG. 5(A) - 5(E) show the effects of treatment with low and high doses of vitamin MK-7 treatment on plaque size and composition in ApoE/LDLR^{-/-} mice. Changes in internal wall area (A: IWA), plaque area (B: expressed as percent of internal wall area:plaque/IWA), lumen area (C: expressed as percent of internal wall area:lumen/IWA), as well as areas of collagen and lipids in plaque (D: Collagen/plaque and E: Lipid/plaque, respectively) in non-treated ApoE/LDLR^{-/-} mice (white columns) and in ApoE/LDLR^{-/-} mice treated with vitamin MK-7 given at low (0.03 mg/kg b.w./day, black columns) or high dose (10 mg/kg b.w./day, columns with diagonal lines) for two months (Untreated_6m: n=6, MK-7 [0.03 mg/kg]: n=7, MK-7 [10 mg/kg]: n=6). The assessment was performed for the entire vessel (A) and for a divided vessel (B) in proximal, middle and distal parts. Statistics: Statistics: Kruskal Wallis test; *p<0.05, **p<0.01, ***p<0.001 vs. Untreated_6m mice.

[0029] FIG. 6(A) - 6(D) show the methodology of MRI-based assessment of endothelium-dependent response *in vivo*. (A) Coronal view of heart. Image showing position of the imaging layer (red cuboid) used for 3D MRI imaging of the aortic arch (aa). Additionally, following vessels are visible: (1) brachiocephalic artery (BCA), (2) left common carotid artery (LCA) and (3) subclavian artery (LSA). (B) 3D image of aa acquired with the cine IntraGate® FLASH 3D sequence. (C) Sagittal view of the cross-section of mice with abdominal aorta (AA). (D) Coronal view of the cross-section of mice with femoral artery (FA). Endothelial function assessment, expressed as changes in the vessels volume, was performed in BCA, LCA, AA and FA.

[0030] FIG. 7(A)-7(E) show the effects of treatment with vitamin K2 (MK-7) for a period of two to eight weeks, given at a dose of 0.05, 0.5, and 5 mg/kg b.w./day on endothelium-dependent vasodilatation *in vivo* and on nitric oxide production in aorta *ex vivo* in young ApoE/LDLR^{-/-} mice. Changes in FMD response in the femoral artery (A,C) FMD-FA and Ach-response in abdominal aorta (B,D) ACH-AA measured *in vivo* by MRI and NO production (E) NO-AA in *ex vivo* aorta measured by EPR are shown. 11-week-old ApoE/LDLR^{-/-} mice were treated with vitamin K2 - MK-7 given at dose of 0.05 mg/kg b.w./day (n=8, black columns), 0.5 mg/kg b.w./day (n=5-8, columns in chessboard pattern) or 5 mg/kg b.w./day (n=6-8, columns with horizontal lines) for two (measurements at 13 weeks of age) and four weeks (measurements at 15 weeks of age) (A,B). 8-week-old ApoE/LDLR^{-/-} mice were treated with vitamin K2 (MK-7) given at dose of 0.05 mg/kg b.w./day (n=6, black columns), for two weeks (measurements at 10 weeks of age) and eight weeks (measurements at 16 weeks of age) (C,D,E). Results were compared to untreated age-matched ApoE/LDLR^{-/-} mice (n=7-8, white columns). Statistics: A,B,C,D: two-way ANOVA (post hoc: Tukey's test); E: Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001.

[0031] FIG. 8(A)-8(E) show the dose-dependent effects of treatment with vitamin K2 (MK-7) on plasma concentration of vitamin K2 (MK-7) and K2 (MK-4) in young ApoE/LDLR^{-/-} mice. Plasma concentration of vitamin K2 (MK-7) (A), K2 (MK-4) (B), K1 (C), K1 2,3-epoxide (D) and MK4 2,3-epoxide (E) are shown. 11-week-old ApoE/LDLR^{-/-} mice were treated four weeks with K2 (MK-7) given at three doses (0.05 mg/kg b.w./day, n=8, black columns; 0.5 mg/kg b.w./day: n=6, chessboard pattern columns; 5 mg/kg b.w./day: n=8; columns with horizontal lines) and compared to untreated age-matched ApoE/LDLR^{-/-} mice (n=8, white columns). <LOD - < limit of detection, n - number of samples for which concentration of vitamin K2 (MK-7) was above LOD. Statistics: Kruskal Wallis test; *p<0.05, **p<0.01, ***p<0.001.

[0032] FIG. 9 shows the assessment of plaque size and composition using histologic evaluation, specifically representative images of the BCA cross-sections stained with Unna's orcein combined with Martius, Scarlet and Blue trichrom (OMSB). The areas of particular components of atherosclerotic plaque (P) including: Lipid core (Lc), collagen (C), as well as artery lumen (L) and vessel wall area (VWA) were determined after Columbus-based software processing. Internal vessel area (IVA) was determined as sum of plaque area and lumen area.

[0033] FIG. 10(A)-10(G) show the effects of treatment with low and high dose of vitamin K2 (MK-7) on endothelial function *in vivo* (A-B), nitrite (NO₂⁻) and nitrate (NO₃⁻) concentration in plasma (C-D) and coagulation measured by thrombin generation in plasma (E-G) in older ApoE/LDLR^{-/-} mice. Changes in Ach-induced response in brachiocephalic artery (A) ACH-BCA and left common carotid artery (B) ACH-LCA are shown as well as changes in NO₂⁻ (C) and NO₃⁻ (D) concentration in plasma and thrombin activity shown as endogenous thrombin potential (E), peak thrombin concentration (F: Peak) and lag time (G). 24-week-old ApoE/LDLR^{-/-} mice were treated for eight weeks


with vitamin K2 (MK-7) in low dose (0.03 mg/kg b.w./day: n=8-9, black columns) or high dose (10 mg/kg b.w./day: n=6, gray columns) as compared to untreated age-matched ApoE/LDLR^{-/-} mice (n=6-10, white columns). Statistics: A-D: one-way ANOVA; E-G: Mann-Whitney U test, *p<0.05, **p<0.01 vs. Untreated mice.

[0034] FIG. 11 shows the effects of treatment with low and high dose of vitamin K2 (MK-7) on vascular wall area (A) and plaque size (B-D) in older ApoE/LDLR^{-/-} mice. Vessel wall area (A) VWA of BCA, changes in internal wall area (B) IWA, lumen area (C) expressed as percent of internal wall area: lumen/IWA and plaque area (D) expressed as percent of internal wall area: plaque/IWA, are shown. 24-week-old ApoE/LDLR^{-/-} mice were treated for eight weeks with vitamin K2 (MK-7) in low dose (0.03 mg/kg b.w./day: n=7, black columns) or high dose (10 mg/kg b.w./day: n=6) as compared to untreated age-matched ApoE/LDLR^{-/-} mice (n=6, white columns). Statistics: Kruskal Wallis test; *p<0.05, **p<0.01, ***p<0.001 vs. Untreated mice.

[0035] FIG. 12 shows LC-APCI-MS/MS -based assessment of plasma concentration of vitamin K, specifically LC-APCI-MS/MS chromatograms of the various vitamin K homologues.

Detailed Description of the Invention

[0036] Vitamin K and derivatives refers to one or more compounds of Formula 1 and their pharmaceutically or nutritionally acceptable salts:



Formula 1

[0037] wherein R may be any covalently linked organic group including polyisoprenoid residues, esters, ethers, and thiol adducts, preferably R is a compound of Formula 2,




Figure 2

[0038] wherein n is an integer from 1 to 12 and the broken lines indicate the optional presence of a double bond.

[0039] Vitamin K and derivatives thereof, as used herein, refers particularly to phyloquinone (Vitamin K1), dihydrophyloquinone, menaquinone (Vitamin K2) including the short chain menaquinones (particularly MK-4) and the long chain menaquinones (particularly MK-7). Sources of vitamin K which can be used according to the present invention include the following: phyloquinone, from natural sources such as vegetable extracts, fats and oils, synthetic phyloquinone, synthetic vitamin K3 (menadione) and different forms of vitamin K2 : synthetic MK-4, MK-5, MK-6, MK-7, MK-8, MK-9, MK-10, MK-11, MK12 and MK-13, natto (food prepared from fermented soy-bean, rich in MK-7) and other fermented foods and or dairy products.

[0040] Vitamin K enriched foods can be manufactured to provide the daily requirements of vitamin K. For example, vitamin K can be added to food products such as meal replacers, ice cream, chocolates, chewing gums, margarines, sauces, dressings, spreads, bars, sweets, snacks, cereals, beverages such as juices, dairy drinks, powdered drinks, sports drink and energy drinks, by methods as described in EP 1 153 548 and U.S. Patent No. 8,354,129, the entire disclosure of which is incorporated

by reference herein. Alternatively, vitamin K can be included in food supplements such as multivitamins, tablets, capsules, elixirs, chews, gummies and other supplement forms. One preferred nutritional formulation comprises 50 µg-1.5 mg vitamin K; 5-10 µg vitamin D; 450-550 mg calcium; 7-12 mg zinc; and 100-200 mg magnesium.

[0041] The dose of vitamin K useful in carrying out the method is not restricted but varies depending on for example, the age of subject and the degree of cardiovascular dysfunction, endothelial dysfunction, the degree of arterial stiffening, the degree of calcification of the blood vessel and the degree of reverse calcification desired. Currently the recommended daily dose of vitamin K is 120 µg for men and 90 µg for women. The benefits of improved cardiovascular function, elasticity, endothelial function, reduced arterial stiffness, increased endothelial nitric oxide production, and/or reduced calcification can be derived at doses higher than the recommended values, particularly in groups where vitamin K deficiencies are common, such as post-menopausal women, or may be derived at doses lower than the recommended values. For example, suitable doses may be in the range of 10 µg to 2000 mg of vitamin K, more preferably 100 µg to 50 mg, 200 µg to 20 mg, or 400 µg to 10 mg. In some embodiments, suitable doses may be 150 to 5000 µg/day, 150-500 µg/day, 10 to 2000 µg/day, optionally 50-1000 µg/day, optionally 150-500 µg/day, and optionally 180-360 µg/day; 70 to 14,000 µg/week or 350 to 7000 µg/week. In terms of body weight, daily dosage may vary from 0.03 to 10 mg/kg body weight/day or 0.5 to 300 µg/kg body weight/day, preferably 1 to 100 µg/kg and most preferably 2 to 40 µg/kg/day.

[0042] As used herein, the term "effective amount" or "therapeutically effective amount" are interchangeable and refer to an amount that results in an improvement, reversal or remediation of the symptoms of the disease or condition.

[0043] The vitamin K can be administered for a period of less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. Preferably, improvement occurs in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K is administered for 2-20 weeks or 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks. If desired, the dosage can be started at an initial dosage until improvement occurs and/or is observed, then lowered to a maintenance dose after sufficient improvement has occurred.

[0044] Vitamin D can be included together with the vitamin K in the composition and may play a role in supporting the function of vitamin K. Any form of natural or synthetic vitamin D may be employed, including vitamin D1, vitamin D2 (calciferol), vitamin D3 (cholecalciferol) and vitamin D analogues (e.g. alfacalcidol, dihydrotachysterol, calcitriol). Natural sources of vitamin D include saltwater fish, organ meats, fish-liver oils and egg yolk. Suitable dosages of vitamin D are 2 to 50 µg/day, preferably 5 to 20 µg/day, and most preferably about 7 to 10 µg/day.

[0045] The medicament or nutritional formulation can contain one or more additional components. Such additional components are preferably selected from: polyphenols, vitamin C, vitamin E (tocopherols and/or tocotrienols), L-Arginine, phytosterols, antihypertensive peptides, soluble fibers (e.g. guar, pectin), omega-3, omega-6 and/or omega-9 fatty acids, carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12. The medicament or nutritional formulation can also be administered simultaneously, separately or sequentially with a medicament selected from the group consisting of anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, anticanginals, hypolipidaemic

agents, beta-blockers, ACE inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics and calcium antagonists.

[0046] The preferred route of administration of vitamin K is enterally, especially orally, but parenteral or topical routes can also be used. "Oral administration" as used herein includes oral, buccal, enteral or intragastric administration. The term "parenteral administration" as used herein includes any form of administration in which the vitamin K is absorbed into the blood stream without involving absorption via the intestines. Exemplary parenteral administrations that are used in the present invention include, but are not limited to intramuscular, intravenous, intraperitoneal, intraocular, subcutaneous or intraarticular administration. If topical administration is desired, physical or chemical drug delivery systems can be used to enhance skin penetration.

[0047] Vitamin K is conventionally provided in the form of tablets or capsules, i.e. in a pharmaceutical or dietary supplement format. For pharmaceutical preparations or dietary supplements the vitamin K may be compounded with pharmaceutically acceptable carriers, excipients or diluents in the forms of pills, tablets (coated or uncoated), hard or soft capsules, dragees, lozenges, oral solutions, suspensions and dispersions, syrups or sterile parenteral preparations. Suitable excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate; granulating and disintegrating agents such as cornstarch or alginic acid; binding agents such as starch gelatin or acacia; effervescent; and lubricating agents such as magnesium stearate, stearic acid or talc.

[0048] It is also possible to deliver or administer Vitamin K (optionally together with vitamin D) in a fortified food or beverage product. Preferred nutritional product formats include: juice drinks, dairy drinks, powdered drinks, sports drinks, mineral water, soy beverages, hot chocolate, malt drinks, biscuits, bread, crackers, confectioneries,

chocolate, chewing-gum, margarines, spreads, yogurts, breakfast cereals, snack bars, meal replacements, protein powders, desserts, and medical nutrition tube feeds and nutritional supplements.

[0049] Conventional additives may be included in the compositions of the invention, including any of those selected from preservatives, chelating agents, effervescent agents, natural or artificial sweeteners, flavoring agents, coloring agents, taste masking agents, acidulants, emulsifiers, thickening agents, suspending agents, dispersing or wetting agents, antioxidants, and the like.

[0050] The vitamin K can be provided in the form of a kit containing an initial treatment dosage and a maintenance dosage. The initial treatment dosage is a dosage effective to induce improvement in cardiovascular function, elasticity, pulse wave velocity or endothelial function, reduction in arterial stiffness and/or the removal of pre-existing calcium deposits within the blood vessel wall in less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 6 weeks, less than 4 weeks, or less than 2 weeks. In some embodiments, the vitamin K initial treatment dosage is administered for 2-20 weeks or 2-16 weeks, preferably 2-12 weeks, 2-8 weeks, 2-less than 6 weeks, or 2-4 weeks. The maintenance dosage is intended for long term administration after the initial treatment period is finished. Preferably, the dosages are in a form for oral administration, preferably in the form of tablets or capsules. Preferably, the maintenance dosage is provided in an amount sufficient for 1 week-36 months.

[0051] In various embodiments, the vitamin K is administered to a mammal including humans, as well as pet animals such as dogs and cats, laboratory animals, such as rats and mice, and farm animals, such as sheep, horses and cows. Patients who would benefit from improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels, include but are not limited anyone at risk from

cardiovascular disorders or already suffering from conditions such as angina pectoris, hypertension, a history of stroke, and other cerebrovascular disorders. Particular target population groups are: postmenopausal women, diabetics, obese individuals, smokers, alcoholics, sedentary and inactive people, the elderly, hemodialysis patients, men over 40 years of age, people suffering from chronic stress, and those consuming an unhealthy diet prone to causing endothelial dysfunction, arterial stiffness and calcification of blood vessels. Patients who would benefit from improving endothelial function include those suffering from hypercholesterolemia, including patients suffering from familial hypercholesterolemia. As used herein, "hypercholesterolemia" refers to the condition characterized by high levels of cholesterol in the blood either in the absence or in the presence of atherosclerotic plaques.

[0052] In various embodiments of the present invention, by quickly improving cardiovascular function, elasticity, endothelial function or pulse wave velocity, reducing arterial stiffening and/or reversing calcification, vitamin K can be used to treat hypertension, left ventricular hypertrophy, congestive heart failure, myocardial infarction, stroke and coronary heart disease. "Elevated blood pressure" or "hypertension" as used herein refers to a blood pressure persistently exceeding 140/90 mmHg (systolic/diastolic). Diseases/conditions associated with pathological calcification, include but are not limited to, calcification of cartilage (osteoarthritis), inflammation-induced calcification (e.g. in Bechterev's disease), tumor-induced calcification (often seen in breast cancer), hyperparathyroidism, hyperphosphatemia, skin calcification such as in pseudoxanthoma elasticum (PXE), and calcifylaxis in end-stage renal disease.

[0053] Non-drug/nutritional treatment modalities for arteriosclerosis involve catheter-based procedures, such as angioplasty, that use a catheter inserted into an artery to press the plaque against the walls of the arteries to increase space for blood to

flow. Stenting, usually done after angioplasty, uses a wire mesh tube placed in the damaged artery to support the arterial walls and is used to keep the vessel open. Atherectomy can be performed where instruments inserted via a catheter are used to cut away and remove plaque so that blood can flow more easily. Administering vitamin K according to the present invention can reduce or avoid the need for catheter-based or surgical treatment of atherosclerosis without delaying catheter-based or surgical treatment for extended periods of time, when necessary.

[0054] Endothelial dysfunction is a pathological condition associated with impaired vasodilation (imbalance between relaxing and contracting factors) as well as changes in the proinflammatory state and prothrombic properties. Endothelial function can be measured by any suitable means, including but not limited to intracoronary infusion of an endothelium dependent vasodilator (e.g. acetylcholine) and quantitative coronary angiography (QCA) or intravascular ultrasound (IVUS); administering an endothelium dependent vasodilator in increasing concentration and determining the changes in coronary blood flow (CBF); measuring changes in forearm blood flow by venous plethysmography before and after administration of vasoactive substances; flow mediated vasodilation of the brachial artery (FMD); and peripheral arterial tonometry (PAT).

[0055] As used herein, the term "reversing calcification" includes removing pre-existing calcium deposited in and/or on a blood vessel. Calcification can be detected by any suitable means, including but not limited to thallium stress testing, radiography, coronary calcification scans, fluoroscopy, CT, angioplasty, MRI imaging, sonography, biopsy, by histochemistry or the like.

[0056] As used herein, the term "arterial stiffness" refers to the mechanical properties of arteries, including the elasticity (or compliance) of the arteries. Arterial

stiffness can be measured by any suitable means, including but not limited to pulse pressure, pulse wave velocity, pulse waveform analysis, and localized assessment of blood vessel mechanics.

[0057] As used herein, the term “increasing endothelial nitric oxide production” includes positively affecting nitric oxide production by the endothelium such that a subject’s endothelium produces more nitric oxide during and/or after treatment as compared with the endothelial nitric oxide production observed prior to treatment. According to some aspects, increased endothelial nitric oxide production may correspond with increased nitrite plasma concentrations in the subject, which may be a reliable marker of endothelial function.

[0058] The following examples are provided as representative of preferred embodiments and are not intended to limit the scope of the present invention.

Example 1

[0059] Clinical Study to study the efficacy and safety of Vitamin K2 supplementation on arterial stiffness, the rigidity of arterial walls, in kidney transplantation patients.

[0060] A clinical study was carried out. Arterial wall property measurements were taken at t=0 and t=8 weeks and show a dramatic improvement in arterial wall flexibility. This is good support for concluding that the ingestion of vitamin K, even over this short period, is an effective way of improving endothelial function, reducing arterial stiffness and reducing calcification. This is in stark contrast to previous studies (EP 1 728 507) that showed significantly reduced arterial stiffness only after 3 years of ingestion. It is surprising and unexpected because calcification is a slow progressive process and it was thought that reversing this process would also be slow and progressive. This

example shows that the preferred treatment period to reverse calcification can be as short as 2 weeks.

[0061] Participants were enrolled in a clinical trial in which the effects of vitamin K2 were determined for patients who had recently undergone a kidney transplant. At the beginning of the study, patients were subjected to a non-invasive pulse wave velocity measurement to measure arterial stiffness/flexibility, as well as blood analysis. The study participants were then instructed to receive a specific daily dose of MenaQ7 vitamin K2 menaquinone-7 (360 ug/day) for a total of 8 weeks. At the end of 8 weeks, patients were again examined with a follow-up examination, a non-invasive pulse wave velocity measurement and blood analysis and drug treatment was discontinued.

[0062] As part of the blood analysis, carboxylated matrix gla protein (MGP) was measured as a direct measure of vitamin K2 activity. The carboxylated MGP inhibits calcification of blood vessels and Vitamin K2 stimulates carboxylation of MGP. Patients undergoing dialysis exhibit deficiencies of vitamin K2 which may impair carboxylation of the calcification inhibitor matrix gla protein (MGP).

[0063] After 8 weeks of treatment, mean reduction in measured pulse-wave velocity was 30%. After 8 weeks of treatment, mean reduction of levels of uncarboxylated MGP was 55%.

Example 2

[0064] The effects of low-doses (0.03 mg/kg b.w./day) as well as high-doses (10 mg/kg b.w./day) of vitamin K2 (MK-7), on endothelial function in mice with pre-established atherosclerosis was assessed. The mice were treated with K2 (MK-7) for two months and endothelial function was analyzed *in vivo* based on functional study (MRI based assessment of NO-dependent vasodilation) as well as by biochemical

analysis (plasma nitrate and nitrite concentration). In addition, a comprehensive qualitative and quantitative histological analysis of the effects of K2 (MK-7) on vascular wall structure and atherosclerosis plaque composition was performed.

[0065] Example 2(a): Materials and Methods

- [0066]** Animals 4-month old ApoE/LDLR^{-/-} mice (n = 76), treated for a two-month period with vitamin K2 - MK-7 (menaquinone-7; doses: 0.03 and 10 mg/kg
- [0067]** Endpoint assays Magnetic resonance imaging (MRI)-based assessment of nitric oxide (NO)-dependent vasodilatation in brachiocephalic (BCA) and left common carotid artery (LCA) after acetylcholine (Ach) administration - by MRI 9.4T scanner, total time of measurements: 114 h (1.5 h per animal), acetylcholine (Ach, 16.6 mg/kg b.w.)
Nitrite (NO₂⁻) and nitrate (NO₃⁻) concentration in plasma - HPLC-based ENO-20
Plaque size and composition as well as vessel wall area (VWA) in BCA - Histological assessment, cross-section method, BCA cross-sections: total 13000 slides, Photographed: 1214 slides

[0068] Human contribution 6 persons involved in carrying out the experiments and data analysis

[0069] Studies were performed on 4-month old female ApoE/LDLR^{-/-} mice, the model initially described by Ishibashi S, Herz J, Maeda N, Goldstein J, Brown M. *The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.* Proc Natl Acad Sci U S A 1994;10:4431–5., and extensively characterized in previous studies, [see Kostogrys RB, Franczyk-Zarow M, Gasior-Glogowska M, Kus E, Jaształ A, Wrobel TP, et al. *Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR^{-/-} mice.* Pharmacol Reports 2017;69:112–8. doi:10.1016/j.pharep.2016.09.014; Tyrankiewicz U, Skorka T, Orzylowska A, Jablonska M, Jasinski K, Jaształ A, et al. *Comprehensive MRI for the*

detection of subtle alterations in diastolic cardiac function in apoE/LDLR -/- mice with advanced atherosclerosis. NMR Biomed 2016;29:833–40. doi:10.1002/nbm.3524; Mateuszuk L, Jaształ A, Maslak E, Gasior-Glogowska M, Baranska M, Sitek B, et al. *Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid.* J Pharmacol Exp Ther 2016;356:514–24. doi:10.1124/jpet.115.228643; Wrobel TP, Marzec KM, Chlopicki S, Maślak E, Jaształ A, Franczyk-Żarów M, et al., *Effects of Low Carbohydrate High Protein (LCHP) diet on atherosclerotic plaque phenotype in ApoE/LDLR-/- mice: FT-IR and Raman imaging.* Sci Rep 2015;5:14002. doi:10.1038/srep14002; Kostogryś RB, Franczyk-Żarów M, Maślak E, Gajda M, Mateuszuk L, Jackson CL, et al., *Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR(-/-)).* Atherosclerosis 2012;223:327–31. doi:10.1016/j.atherosclerosis.2012.05.024; Csányi G, Gajda M, Franczyk-Zarow M, Kostogryś R, Gwoźdź P, Mateuszuk L, et al. *Functional alterations in endothelial NO, PGI2 and EDHF pathways in aorta in ApoE/LDLR-/- mice.* Prostaglandins Other Lipid Mediat 2012;98:107–15. doi:10.1016/j.prostaglandins.2012.02.002.). Mice were randomly assigned to three experimental groups: control - untreated group and two groups treated for two months with low or high doses of menaquinone-7 (MK-7, 0.03 and 10 mg/kg b.w./day, respectively, given with the food, MK-7 provided by Pharmaceutical Research Institute, Warszawa via courtesy of Dr. Maresz]. For the assessment of endothelium-dependent vascular responses *in vivo* 6-month old mice were imaged using MRI-based methods as described previously [See Bar A, Skorka T, Jasinski K, Sternak M, Bartel Ź, Tyrankiewicz U, et al. *Retrospectively-gated MRI for in vivo assessment of endothelium-dependent vasodilatation and endothelial permeability in murine models of endothelial dysfunction.*

NMR Biomed 2016;29(8):1088; Bar A, Skorka T, Jasinski K, Chlopicki S. *MRI-based assessment of endothelial function in mice in vivo*. Pharmacol Reports 2015;67:765–70. doi:10.1016/j.pharep.2015.05.007]. During the experiment mice were anaesthetized using isoflurane (1.7 vol%) in an oxygen and air (1:2) mixture. Vasomotor response of the vessels was examined by comparing two, time-resolved 3D images (Fig.1) of the aortic arch prior to and 25 minutes after intraperitoneal Ach administration (Sigma-Aldrich, Poznań Poland, 50 µl, 16.6 mg/kg b.w.). Images were acquired using the cine IntraGate™ FLASH 3D sequence. End-diastolic volumes of BCA and LCA were analyzed using ImageJ software (1.46r NIH Bethesda, Maryland, USA) and scripts written in Matlab (MathWorks, Natick, MA, USA) (Fig.1A).

[0070] After *in vivo* measurements the mice were injected intraperitoneally with 1000 IU of heparin (Sanofi-Synthelabo; Paris, France) and after 10 min, anesthetized intraperitoneally with 40 mg/kg b.w. of sodium thiopental (Biochemie; Vienna, Austria). Blood samples were collected from heart into test tubes containing additional anticoagulant and centrifuged at 1000 g for 10 min at 4°C. The samples were used for HPLC measurement of nitrate (NO₃⁻) and nitrite (NO₂⁻) concentrations in plasma by an ENO-20 NOx Analyzer.

[0071] For the determination of atherosclerotic plaque area and composition BCA was dissected, fixed in 4% buffered formalin and embedded in paraffin. 5 µm-thick serial sections of BCA were collected from proximal, middle and distal parts of artery. Originally developed staining with Unna's orcein combined with Martius, Scarlet and Blue trichrome (OMSB), was applied on every tenth section (50 µm interval between each section) for visualization of collagen, elastin, fibrin, red blood cells and vascular smooth muscle cells within atherosclerotic plaque. The areas of particular components of atherosclerotic plaque as well as artery lumen and wall were determined after Columbus-

based software processing (Fig.1B) using a previously developed algorithm [Gajda M, Jaształ A, Banasik T, Jasek-Gajda E, Chlopicki S. *Combined orcein and martius scarlet blue (OMSB) staining for qualitative and quantitative analyses of atherosclerotic plaques in brachiocephalic arteries in apoE/LDLR^{-/-} mice*. Histochem Cell Biol 2017. doi:10.1007/s00418-017-1538-8.].

Example 2(b): Description of Results

Effects of treatment with low and high dose of vitamin MK-7 on endothelium-dependent vasomotor response in ApoE/LDLR^{-/-} mice *in vivo*.

[0072] In 6-month old non-treated ApoE/LDLR^{-/-} mice, injection of Ach (16.6 mg/kg b.w. given i.p. in the volume of 50 µl) resulted in constriction of BCA and LCA amounting to -9.13% in BCA and -28.33% in LCA.

[0073] A two-month treatment with low doses of vitamin MK-7 was sufficient to improve endothelial function as evidenced by partial reversal of the Ach-induced vasoconstriction response. An increase in volume of BCA (Fig.2A) and LCA (Fig.2B) after Ach injection was observed (vessel volume changes: about 3% and -3%, respectively). Treatment of ApoE/LDLR^{-/-} mice for two months with high doses of vitamin MK-7 also resulted in the improved endothelium-dependent vasodilatation induced by Ach in LCA and BCA. Although the mean results for Ach-induced response in groups treated with low (volume changes: 3.25% and -3.92% for BCA and LCA respectively) and high (volume changes: 3.12% and 4.45% for BCA and LCA respectively) dose of vitamin MK-7 were similar the improvement of endothelial function in the high dose group was more significant due to more homogenous response and lower standard errors.

Effects of treatment with low and high dose of vitamin MK-7 on plasma nitrite and nitrate concentration

[0074] Treatment of ApoE/LDLR^{-/-} mice for two months with low as well as high doses of vitamin MK-7 resulted in an increase in NO₂⁻ concentration (Fig. 3A) in plasma (by about 58% and 42%, respectively). The concentration of NO₃⁻ (Fig. 3B) in plasma did not change significantly in ApoE/LDLR^{-/-} mice treated with vitamin MK-7 neither in doses of 0.03 mg/kg b.w./day nor 10 mg/kg b.w./day.

Effects of treatment with low and high dose of vitamin MK-7 on vessel wall structure and media thickness

[0075] As shown in Fig. 4A treatment with vitamin MK-7 resulted in a clear-cut effect on vessel wall area (VWA), the parameter representative for media layer thickness of the vascular wall. In mice treated for two months with vitamin MK-7, VWA decreased significantly (by about 5%, similarly for low and high dose of vitamin MK-7). Effect was more pronounced in middle and distal part of the vessel in ApoE/LDLR^{-/-} mice treated with lower dose (0.03 mg/kg b.w./day) and in proximal part of the vessel in ApoE/LDLR^{-/-} mice treated with higher dose (10 mg/kg b.w./day) of vitamin MK-7 (Fig. 4B) suggesting stronger effects of low dose of vitamin MK-7 on vascular wall structure in the middle part of the BCA, that part of the BCA characterized by the presence of earliest, least advanced plaques and less advanced vascular pathology.

Effects of treatment with low and high doses of vitamin MK-7 on atherosclerotic plaque size and composition

[0076] Two-month treatment of ApoE/LDLR^{-/-} mice with vitamin MK-7 either low or high doses did not result in a beneficial effect on plaque size . Internal wall area (IWA,

Fig.5A), which is the sum of plaque and lumen areas, decreased only in the middle part of the vessel, in mice treated with lower doses of vitamin MK-7, and this effect was not visible for entire vessel. Consequently, plaque and lumen area expressed as percent of IWA (Fig. 5B - 5C) did not change, in mice treated with either low or high doses of vitamin MK-7. However, despite the lack of differences between treated and untreated groups in the content of collagen in plaque (Fig. 5D), significant changes in atherosclerotic plaque composition were observed. In ApoE/LDLR^{-/-} mice treated with low or high dose of vitamin MK-7 lipid core expressed as percent of plaque (Fig. 5E) decreased after two-month treatment either with lower or higher doses of vitamin MK-7 (by about 17%, similarly after low and high dose). Specifically, changes in the content of lipids in plaque were visible in middle part of the BCA with least advanced plaques and the proximal part of the BCA with plaques formed distal to the bifurcation, but not in distal parts with plaques formed proximal to bifurcation.

Example 2(c): Conclusions

[0077] In ApoE/LDLR^{-/-} mice with advanced atherosclerosis, treatment with vitamin K2 (MK-7) for two months improved endothelial function *in vivo*, as evidenced by improvement of functional endothelial-dependent responses induced by acetylcholine *in vivo*, a well validated measure to assess NO-dependent function [Bar A, Skorka T, Jasinski K, Sternak M, Bartel Ž, Tyrankiewicz U, et al. *Retrospectively-gated MRI for in vivo assessment of endothelium-dependent vasodilatation and endothelial permeability in murine models of endothelial dysfunction*. NMR Biomed 2016;29(8):1088] as well as by increased plasma nitrite concentration, the parameter that reflects endothelial NO-dependent function [Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, et al. *Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals*.

Free Radic Biol Med 2003;35:790–6; Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. *Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans*. Free Radic Biol Med 2006;40:295–302. doi:10.1016/j.freeradbiomed.2005.08.025]. Even low doses of vitamin K2 (0.03 mg/kg b.w./day) had a significant effect. To our knowledge the effects of vitamin K2 on endothelial function has been described here for the first time. Whether the mechanisms of improvement of endothelial function by vitamin K2 are related to canonical or non-canonical mechanisms of action of vitamin K2 requires further mechanistic studies.

[0078] The known effect of vitamin K2 on vascular structure was also confirmed, as treatment with vitamin K2 (MK-7) resulted in a significant decrease in media thickness as evidenced by a decrease in vessel wall area. This effect could be linked to known mechanism of vitamin K2 –dependent carboxylation of matrix Gla-protein in smooth muscle cells [Schurgers LJ, Uitto J, Reutelingsperger CP. *Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization*. Trends Mol Med 2013;19:217–26. doi:10.1016/j.molmed.2012.12.008], and was the most pronounced in the middle part of the BCA, the part of the vessel with earliest, least advanced atherosclerotic plaques.

[0079] Although treatment with vitamin K2 (MK-7) did significantly affect the structure of the media layer of the vessel wall, there was no substantial effect of vitamin K2 (MK-7) on the size of the atherosclerotic plaque. These results are not surprising, given the fact that ApoE/LDLR^{-/-} mice with advanced atherosclerosis were used in this study and vitamin K2 was not expected to possess strong anti-atherosclerotic activity. On the other hand, treatment with vitamin K2 (MK-7) substantially changed plaque composition and particularly, the lipid/plaque ratio. The effects of vitamin K2 (MK-7) on plaque composition was the most pronounced in the middle part of the BCA with the

earliest atherosclerotic plaques. This result suggests distinct anti-inflammatory effects of vitamin K2 that could translate into pronounced anti-atherosclerotic action if the experiments were carried out in a model with early stages of atherosclerotic plaque development. This result also suggests that treatment with vitamin K2 could have a preventive action on atherosclerotic plaque development.

[0080] Altogether, the results presented here provide convincing evidence that apart from its known pharmacological activity on media thickness and other matrix Gla-protein–dependent mechanisms in smooth muscle cells reported previously [Schurgers LJ, Uitto J, Reutelingsperger CP. *Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization*. Trends Mol Med 2013;19:217–26. doi:10.1016/j.molmed.2012.12.008], vitamin K2 improves endothelial function and limits the inflammatory burden of atherosclerotic plaques. The endothelial action of vitamin K2, may be related to K2–dependent carboxylation mechanisms. Whatever is the mechanism, improvement of endothelial function afforded by vitamin K2 may contribute to the improvement of vascular stiffness, that was reported to be improved by vitamin K2 [Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C. *Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women*. Thromb Haemost 2015;113:1135–44. doi:10.1160/TH14-08-0675]. In fact, vascular stiffness is known to be regulated by endothelial function and improvement of endothelial function improve vascular stiffness [Daiber A, Steven S, Weber A, Shuvaev V V., Muzykantov VR, Laher I, et al. *Targeting vascular (endothelial) dysfunction*. Br J Pharmacol 2016. doi:10.1111/bph.13517; O'Rourke MF, Hashimoto J. *Arterial Stiffness*. J Cardiopulm Rehabil Prev 2008;28:225–37. doi:10.1097/01.HCR.0000327179.21498.38]. Furthermore, given the fact that the endothelium is involved in most if not all disease states, either as a primary determinant

of pathophysiology or as a victim of collateral damage [Chlopicki S. *Perspectives in pharmacology of endothelium: From bench to bedside*. Pharmacol Reports 2015;67:vi – ix. doi:10.1016/j.pharep.2015.08.005; Frolow M, Drozd A, Kowalewska A, Nizankowski R, Chlopicki S. *Comprehensive assessment of vascular health in patients; towards endothelium-guided therapy*. Pharmacol Rep 2015;67:786–92. doi:10.1016/j.pharep.2015.05.010], the finding of the effect of vitamin K2 on endothelial function suggests a novel therapeutic perspective for vitamin K2 as a vasoprotective agent in various diseases/conditions associated with endothelial dysfunction, for example in diabetes, hypertension, atherosclerosis, heart failure, neurodegenerative diseases, kidney transplant patients, hemodialysis patients and many others.

Example 3

[0081] In a first part of the study, the effects of low doses (0.05 mg/kg b.w./day) as well as higher doses (0.5 mg/kg b.w./day and 5 mg/kg b.w./day) of vitamin K2 (MK-7, referred to in this example as simply “vitamin K2,” unless noted otherwise) on endothelial function in ApoE/LDLR^{-/-}-mice without well-established atherosclerotic plaque and with early phase of endothelial dysfunction were assessed.

[0082] In a second part of the study, the effects of a low dose (0.03 mg/kg b.w./day) as well as a high doses (10 mg/kg b.w./day) of vitamin K2 (MK-7) on endothelial function in ApoE/LDLR^{-/-}-mice with pre-established atherosclerosis were assessed.

[0083] In the first part of the study, the mice were treated with vitamin K2 (MK-7) for two, four, or eight weeks. In the second part of the study), the mice were treated with vitamin K2 (MK-7) for eight weeks.

[0084] The endothelial function was analyzed *in vivo* based on functional studies (MRI based assessment and assessment of NO production in aorta using electron paramagnetic resonance) as well as by biochemical analysis (plasma nitrate, nitrite, and vitamin K concentration, and a thrombin generation assessment using a Calibrated Automated Thrombogram). In addition, a comprehensive qualitative and quantitative histological analysis was performed.

Example 3(a): Materials and Methods

[0085] In the first part of the study, male mice without well-established atherosclerotic plaques and with early phase of endothelial dysfunction (8-11 weeks of age) were used to examine the effects of two-, four-, and eight-week treatments with a low dose (0.05 mg/kg b.w./day) or higher doses (0.5 and 5 mg/kg b.w./day) of vitamin K2 (MK-7). Mice were randomly assigned to one of four experimental groups: control (untreated group) and three groups treated with vitamin K2 at a dose of 0.05, 0.5, and 5 mg/kg b.w./day, respectively. End-point measurements were performed at the age of 10-16 weeks.

[0086] In the second part of the study, female mice with advanced endothelial dysfunction and pre-established atherosclerosis (16 weeks of age) were treated with K2 (MK-7) for 8 weeks. In this part of the study, mice were randomly assigned to one of three experimental groups: control (untreated group) and two groups treated with low and high doses (0.03 and 10 mg/kg b.w./day, respectively). End-point measurements were performed at the age of 24 weeks.

[0087] To perform both studies, vitamin K2 was dissolved in soybean oil and administrated as a part of a semi-synthetic AIN 93G diet as shown in Table 1, without or with a standard vitamin mixture containing vitamin K1.

[0088] Mice were housed in collective cages in a room with constant environmental conditions (22-25°C, 65-75% humidity, and 12 hour light/dark cycle). Animals had ad libitum access to daily provided diets and water.

Table 1

	Untreated female	Untreated male	Dose of K2 - MK-7 [mg/kg]				
			0.03	0.05	0.5	5	10
Corn starch [g]	533						
Caseine [g]	200						
Sucrose [g]	100						
Soybean oil [g]	70						
Cellulose powder	50						
Mineral mixture [g]	35						
Vitamin mixture 1 ¹ [g]	10	-	-	-	-	-	-
Vitamin mixture 2 ² [g]	-	10	10	10	10	10	10
Choline bitartrate	2.5						
t-butylhydroquinone	0.014						
Vitamin MK-7 in diet [mg]	-	-	0.15	0.25	2.50	25.00	50.00
Equivalent dose of MK-7 [mg/kg b.w.]	-	-	0.03	0.05	0.50	5.00	10.00

¹standard vitamin mixture containing 75 mg/kg (equivalent to dose 0.15 mg/kg b.w./day)

vitamin K1

²vitamin mixture without vitamin K1

Assessment of endothelium-dependent vasodilatation in vivo by magnetic resonance imaging (MRI)

[0089] Magnetic resonance imaging (MRI) experiments were performed using a 9.4T scanner (BioSpec 94/20 USR, Bruker, Germany) located in the Department of

Magnetic Resonance Imaging, Institute of Nuclear Physics, Polish Academy of Sciences in Krakow. During the experiment, mice were anaesthetized using isoflurane (Aerrane, Baxter Sp. z o. o., Poland, 1.7 vol%) in an oxygen and air (1:2) mixture and imaged in the supine position. Activity of the heart, respiration, and body temperature (maintained at 37°C using circulating warm water) were monitored using a Monitoring and Gating System (SA Inc., Stony Brook, NY, USA).

[0090] Endothelial function was assessed based on vascular responses to acetylcholine (Ach) administration in brachiocephalic artery (BCA), left common carotid artery (LCA) (Fig. 6 A and B) and abdominal aorta (AA) (Fig. 6C) as well as to responses to increase in flow (flow-mediated dilatation, FMD) in femoral artery (FA) (Fig. 6D) as described in Bar A, Skorka T, Jasinski K, Sternak M, Bartel Ż, Tyrankiewicz U, et al. Retrospectively-gated MRI for in vivo assessment of endothelium-dependent vasodilatation and endothelial permeability in murine models of endothelial dysfunction. *NMR Biomed* 2016;29(8):1088.; Sternak M, Bar A, Adamski MG, Mohaissen T, Marczyk B, Kieronska A, et al. The Deletion of Endothelial Sodium Channel α (α ENaC) Impairs Endothelium-Dependent Vasodilation and Endothelial Barrier Integrity in Endotoxemia in Vivo. *Front Pharmacol* 2018;9:178. doi:10.3389/fphar.2018.00178.; and Bar A, Olkowicz M, Tyrankiewicz U, Kus E, Jasinski K, Smolenski RT, et al. Functional and Biochemical Endothelial Profiling In Vivo in a Murine Model of Endothelial Dysfunction; Comparison of Effects of 1-Methylnicotinamide and Angiotensin-converting Enzyme Inhibitor. *Front Pharmacol* 2017;8:183. doi:10.3389/fphar.2017.00183.).

[0091] Vasomotor response was examined by comparing two time-resolved 3D images of the vessels prior to and 25 minutes after intraperitoneal Ach administration (Sigma-Aldrich, Poznań Poland: 50 μ l, 16.6 mg/kg), as well as prior to and 5 minutes after vessel occlusion. Images were acquired using the cine IntraGate™ FLASH 3D

sequence, reconstructed with the IntraGate 1.2.b.2 macro (Bruker). End-diastolic volumes of vessels were analyzed using ImageJ software 1.46r (NIH Bethesda, Maryland, USA) and scripts written in Matlab (MathWorks, Natick, MA, USA). Imaging parameters included the following: repetition time (TR) - 6.4 ms, echo time (TE) - 1.4 ms, field of view (FOV) - 30x30x5 mm³, matrix size - 256x256x30, flip angle (FA) - 30°, and number of accumulations (NA) - 15, reconstructed to 7 cardiac frames. Total scan time was 10 minutes.

Assessment of endothelial NO production in aorta using electron paramagnetic resonance

[0092] For measurements of endothelial nitric oxide synthase (eNOS)-dependent nitric oxide (NO) production, EPR spin-trapping with diethyldithiocarbamic acid sodium salt (DETC) was used *ex vivo*, as described in Przyborowski K, Proniewski B, Czarny J, Smeda M, Sitek B, Zakrzewska A, et al. Vascular Nitric Oxide–Superoxide Balance and Thrombus Formation after Acute Exercise. *Med Sci Sport Exerc* 2018:1. doi:10.1249/MSS.0000000000001589, with minor modifications. Isolated aorta cleared from surrounding tissue was opened longitudinally and preincubated with 10 μM L-NIL (N6-(1-Iminoethyl)-lysine, hydrochloride) in Krebs-HEPES buffer for 30 minutes at 37 °C in a well of a 48-well plate. Next, 250 μL of Fe(DETC)₂ colloid was added and aorta was stimulated with calcium ionophore A23187 (the final concentration was 1 μM) and subsequently, incubated for 90 minutes at 37 °C. Finally, aorta was weighed and frozen in liquid nitrogen (suspended in fresh buffer) into the middle of a 400 μL column of Krebs–Hepes buffer and stored at -80 °C until measured. EPR spectra were obtained using an X-band EPR spectrometer (EMX Plus, Bruker, Germany), equipped with a rectangular resonator cavity H102. Signals were quantified by measuring the total amplitude of the

NO-Fe(DETC)₂ after correction of baseline. The quantitative results of NO production assessed by EPR were expressed in AU/mg of tissue.

Blood sampling and biochemical analysis

[0093] After *in vivo* MRI measurements the mice were injected intraperitoneally with 1000 IU of heparin (Sanofi-Synthelabo; Paris, France) and after 15 minutes, anesthetized intraperitoneally with 100 mg/kg b.w ketamine + 10 mg/kg b.w xylazine mg/kg b.w. Blood samples were collected from the heart into test tubes containing additional anticoagulant. On the same day, 25 μ L of whole blood was used for blood count analysis, using automatic biochemistry analyzer ABX Pentra 400 (Horiba Medical, Kyoto, Japan). Remaining blood was centrifuged at 1000 g for 10 minutes in 4°C and plasma was deep frozen for HPLC measurement of nitrate (NO³⁻) and nitrite (NO²⁻) concentrations by ENO-20 NOx Analyser, or for lipid profile and liver enzyme analysis by biochemical analyzer (ABX Pentra 400 - Horiba Medical, Kyoto, Japan). Moreover, L-APCI-MS/MS-based assessment of vitamin K derivatives concentration was performed as described below in plasma samples obtained from blood samples collected with EDTA K2 and Protease Inhibitor Cocktail that were centrifuged at 1000 g for 10 minutes in 4°C.

LC-APCI-MS/MS based assessment of plasma concentration of vitamin K

[0094] To measure concentration of vitamin K₂ and also other vitamin K derivatives (i.e., vitamin K₁ – phylloquinone (PK) and MK-4) in plasma, a selective and sensitive method based on high performance liquid chromatography-tandem mass spectrometry with atmospheric pressure chemical ionization technique (LC-APCI-MS/MS) was developed. The methodology was based on Riphagen IJ, van der Molen

JC, van Faassen M, Navis G, de Borst MH, Muskiet FAJ, et al. Measurement of plasma vitamin K1 (phylloquinone) and K2 (menaquinones-4 and -7) using HPLC-tandem mass spectrometry. Clin Chem Lab Med 2016;54:1201–10. doi:10.1515/cclm-2015-0864., with some adjustments.

[0095] An individual stock solution of analytes (K1, MK-4, and MK-7) and internal standard (K1-d7) of 100 µg/mL were prepared by dissolving the 1 mg of standards in 10 mL of ethanol. A standard mixture stock solution of 10 µg/mL was prepared in ethanol. The individual stock solutions and standard mix were stored in dark at -20°C prior to use. For the analytical curves, working solutions of standard mixture ranging from 0.5 ng/mL to 10 µg/mL were prepared by dilution of stock solution with ethanol. The internal standard working solution of 1 µg/mL was prepared by diluting K1-d7 stock solution with ethanol. A calibration curve samples were prepared by mixing 90 µL of blank plasma samples with 10 µL of appropriate standard working solution mixture. The concentration of calibration points were equivalent to 0.05; 0.1; 0.25; 0.5; 0.75; 1; 2.5; 5; 10; 25; 50; 100; 200; 400; 600; 750; 1000 ng/mL.

[0096] An aliquot of 100 µL of plasma in amber tubes was spiked with 10 µL of internal standard – vitamin K1-d7 (1 µg/mL in ethanol). Extra ethanol (200 µL) was added to denature the protein, briefly mixed and 1 mL of hexane, followed by shaking for 15 minutes. The solution was centrifuged at 15.000 rpm for 15 minutes, and the upper layer was quantitatively transferred to a new tube and evaporated under the stream of nitrogen at room temperature. The residue was dissolved with 30 µL of 2-propanol, centrifuged at 15.000 rpm for 15 minutes, and 5 µL was injected into the column.

[0097] The HPLC analysis was conducted with an Ultimate 3000 HPLC system (Dionex, Sunnyvale, CA, US). Separations were carried out using a reversed-phase PFP analytical column (Kinetex 2,6 µm PFP, 100 Å, 100.0 x 3.0 mm, Phenomenex, Torrance,

CA, US) with a mobile phase consisted of 0.1% of formic acid in 2-propanol (phase A) and 0.1% formic acid in 5 mM ammonium formate (phase B) in gradient elution. The chromatogram of determined vitamin K derivatives is shown in Figure 12.

[0098] Mass spectrometry was performed with a TSQ Quantum Ultra triple quadrupole mass spectrometer (Thermo Scientific, Waltham, MA, US), equipped with APCI electrospray ion source. All MS analysis were collected in positive ionisation mode. The working parameters of mass spectrometer were as follows: corona discharge needle voltage, 4 kV, vaporiser temperature: 325°C, sheath gas pressure 50 Arb, ion sweep gas pressure 10 Arb, auxiliary gas pressure 30 Arb, capillary temperature 325°C and collision pressure 1.5 mTorr with Argon as a collision gas.

Thrombin generation assessment using Calibrated Automated Thrombogram (CAT)

[0099] Thrombin generation was measured in platelet-poor mice plasma using calibrated automated thrombography (CAT) technique as described in Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. *Pathophysiol Haemost Thromb* 2003;33:4–15. doi:71636. Thrombin generation was activated by mixing 21 µL of diluted plasma (1:1 with BSA5 buffer) with 7 µL of fluorogenic substrate (Z-Gly-Gly-Arg-AMC, 16.6 mM) and 14 µL of trigger solution containing phospholipids, tissue factor and CaCl₂ (4 µM, 1 pM and 16.6 mM, respectively). In the calibration wells, the 14 µL of reagents were replaced with calibrator (102 nM). Immediately after the activation, 5 µL of the mixture was pipetted on paper disks in a flat bottom 96-well polystyrene plate and covered with 40 µL of mineral oil. Fluorescent signals were measured using the Fluoroskan Ascent software (Thermo Labsystems, Helsinki, Finland) and transformed

into thrombin concentration as described in Hemker HC, Kremers R. Data management in Thrombin Generation. *Thromb Res* 2013;131:3–11. doi:10.1016/j.thromres.2012.10.011. The parameters analyzed included endogenous thrombin potential (ETP), peak thrombin concentration (peak), and lag time.

Histological assessment of area and composition of atherosclerotic plaque (cross-section method)

[0100] For the determination of atherosclerotic plaque area and composition isolated brachiocephalic artery (BCA) was dissected, fixed in 4% buffered formalin, and embedded in paraffin. 5 µm-thick serial sections of BCA were collected from the proximal to distal part of the artery. Staining with Unna's orcein combined with Martius, Scarlet and Blue trichrome (OMSB) was applied on every tenth section (50 µm interval between each section) for quantitative analysis of atherosclerotic plaques. The areas of particular components of atherosclerotic plaque as well as artery lumen and wall were determined after Columbus-based software processing (Fig. 9) using specially-designed algorithm as described in Gajda M, Jaształ A, Banasik T, Jasek-Gajda E, Chlopicki S. Combined orcein and martius scarlet blue (OMSB) staining for qualitative and quantitative analyses of atherosclerotic plaques in brachiocephalic arteries in apoE/LDLR^{-/-} mice. *Histochem Cell Biol* 2017. doi:10.1007/s00418-017-1538-8. The parameters analyzed include vessel wall area (VWA), internal vessel area (IVA = plaque area + lumen area), plaque area (expressed as percent of internal wall area: plaque/IWA), and lumen area (expressed as percent of internal wall area: lumen/IWA).

Immunohistochemical detection of macrophages in atherosclerotic plaque in BCA

[0101] For detection of macrophages in BCA, atherosclerotic plaque immunohistochemical staining was performed. After heat-induced epitope retrieval, with 10 mM sodium citrate buffer (pH 6), deparaffinised sections were blocked with 5% normal goat serum and 1% hydrogen peroxide. Macrophages were revealed by overnight incubation with monoclonal anti-Mac-3 antibody (BD Pharmingen, 550292). Next, sections were treated with biotinylated secondary antibody, followed by horseradish peroxidase-conjugated streptavidin. 3,3'-diaminobenzidine (DAB) as a chromogen was used for visualization of antibody-antigen interaction. Sections were counterstained with hematoxylin. Intensity of Mac-3 staining was estimated manually considering quantity and intensity of positive reactions. Final results are shown as a mean from two independent analyses.

Example 3(b): Description of Results

Effects of vitamin K2 treatment on nitric oxide-dependent endothelial function in young ApoE/LDLR^{-/-} mice at the stage prior to advanced atherosclerotic plaque development

[0102] As shown in Figure 7(A-B), the four-week treatment with low dose (0.05 mg/kg b.w./day) of vitamin K2 (MK-7) improved FMD in FA (volume changes: 33.26% in mice treated with K2 and 17.45% in untreated mice, $p < 0.001$) as well as improved Ach response in AA (volume changes: -1.59% in mice treated with K2 and -11.22% in untreated mice, $p = 0.02$) in 15-week-old treated ApoE/LDLR^{-/-} mice as compared with untreated ApoE/LDLR^{-/-} mice. At this age, ApoE/LDLR^{-/-} mice are characterized by full-blown phenotype of endothelial dysfunction but not yet advanced atherosclerosis plaques.

[0103] In contrast to the four-week period of vitamin K2 treatment, the two-week period of treatment with low dose of vitamin K2 (0.05 mg/kg b.w./day) was not sufficient to improve endothelial function, as evidenced by the lack of changes in the magnitude of vasodilatation in response to increase in flow in femoral artery (FMD-FA, Fig. 7A) and in the magnitude of endothelium-dependent response to acetylcholine in abdominal aorta (ACH-AA, Fig. 7B). However, higher doses of vitamin K2 improved endothelial function just after two weeks of treatment (volume changes: 28.57% in FA, p=0.04 and 1.52% in AA, p=0.05 for the dose of 0.5 mg/kg b.w./day and volume changes: 26.55% in FA, p=0.1 and 0.16% in AA, p=0.1 for the dose of 5 mg/kg b.w./day as compared with 20.86% in FA and - 7.72% in AA in untreated mice, respectively).

[0104] The improvement in endothelial function afforded by four weeks of treatment with higher doses of K2 (0.5 mg/kg b.w./day and 5 mg/kg b.w./day) was not superior as compared with that achieved by low dose treatment with K2 administered for 4 weeks (Fig. 7(A-B)), despite the fact, that three doses of vitamin K2 (0.05; 0.5; 5 mg/kg b.w./day) resulted in a dose-dependent increase in plasma concentration of K2 (Fig. 8A) and MK-4 (Fig. 8B). Concentration of MK4 2,3-epoxide (Fig. 8E) in plasma was maintained at similar level in all groups, while vitamin K1 (Fig. 8C) and K1 2,3-epoxide (Fig. 8D) plasma concentration tend to decrease with increasing dose of vitamin K2.

[0105] Moreover, prolongation of the treatment time to eight weeks (Fig. 7C-D) was also not associated with superior effect of treatment as compared with K2 administered at low dose (0.05 mg/kg b.w./day) (volume changes: 28.34% in FA, p=0.03 and -0.65% in AA, p=0.05 as compared with 14.28% in FA and -16.22% in AA in untreated mice, respectively).

[0106] The positive effects of low dose of vitamin K2 (0.05 mg/kg) improving the endothelium-dependent vasodilation measured *in vivo* was confirmed by showing

increased nitric oxide production measured in the same animals by EPR in *ex vivo* aorta, taken from ApoE/LDLR^{-/-} mice treated with low dose (0.05 mg/kg b.w./day) of vitamin K2 (Fig. 2E) as compared with untreated, age-matched ApoE/LDLR^{-/-} mice.

Effects of vitamin K₂ treatment on endothelial function in older ApoE/LDLR^{-/-} mice at the stage of advanced atherosclerosis

[0107] In 24-week-old, non-treated ApoE/LDLR^{-/-} mice, characterized by advanced endothelial dysfunction and presence of atherosclerotic plaques, injection of Ach resulted in constriction of BCA and LCA amounting to -9.13% in BCA and -28.33% in LCA. As shown in Fig. 10(A-B), eight-week treatment with low dose of vitamin K2 (0.03 mg/kg b.w/day) resulted in improvement of endothelial function as evidenced by partial reversal of Ach-induced vasoconstriction response. A change in volume of BCA (Fig. 10A) and LCA (Fig. 10B) after Ach injection was about 3% and -3%, respectively. Treatment of ApoE/LDLR^{-/-} mice for eight weeks with high dose (10 mg/kg b.w/day) of vitamin K2 also resulted in the improved endothelium-dependent vasodilatation induced by Ach in LCA and BCA. The mean results for Ach-induced response in groups treated with low (volume changes: 3.25% and -3.92% for BCA and LCA respectively) and high (volume changes: 3.12% and 4.45% for BCA and LCA respectively) dose of vitamin K2 was similar. However, the improvement of endothelial function in high dose group was more significant due to more homogenous response and lower standard errors.

[0108] Improvement of endothelium-dependent vasodilation by treatment of older ApoE/LDLR^{-/-} mice for eight weeks with low as well as high dose of vitamin K2 resulted in increase in NO₂⁻ concentration (Fig. 10C) in plasma (by about 58% and 42%, respectively). Concentration of NO₃⁻ (Fig. 10D) in plasma did not change significantly in

ApoE/LDLR^{-/-} mice treated with vitamin K2 neither at a dose of 0.03 mg/kg b.w./day nor at a dose of 10 mg/kg b.w./day.

[0109] Eight-week treatment of ApoE/LDLR^{-/-} mice with vitamin K2 of either dose did not affect lipid profile, liver enzymes concentration, blood cell count (Table 2) or thrombin generation (Fig. 10(E-F)).

Table 2

	Untreated mice	MK-7 0.03 mg/kg	MK-7 10 mg/kg
Lipid profile:			
TC (mmol/L)	15.96 ± 4.21	19.96 ± 3.82	16.59 ± 2.89
Triglycerides (mmol/L)	1.24 ± 0.57	2.15 ± 0.46	1.87 ± 0.98
Liver enzymes:			
ALT (U/L)	46.26 ± 17.97	45.20 ± 15.72	47.58 ± 19.55
AST (U/L)	108.48 ± 24.97	97.99 ± 27.89	74.40 ± 20.44
SAA (µg/ml)	35.92 ± 4.48	34.23 ± 10.42	36.63 ± 8.06
Blood count:			
GRA	0.64 ± 0.13	0.73 ± 0.24	0.52 ± 0.22
GRA (%)	16.78 ± 2.89	16.00 ± 6.36	14.08 ± 3.73
Hematocrit	45.57 ± 1.26	49.99 ± 9.02	44.07 ± 7.50
HGB	12.61 ± 1.29	13.81 ± 2.53	12.09 ± 1.77
LYM	2.15 ± 0.58	3.10 ± 1.93	1.6 ± 1.25
LYM (%)	74.27 ± 4.66	75.45 ± 10.25	77.39 ± 4.50
MCH	14.85 ± 0.66	15.13 ± 0.38	14.57 ± 0.18
MCHC	27.74 ± 1.36	28.05 ± 0.39	27.22 ± 0.59
MCV	53.50 ± 1.00	54.00 ± 2.00	53.00 ± 1.00
MON	0.25 ± 0.10	0.30 ± 0.05	0.15 ± 0.20
MON (%)	8.95 ± 2.10	8.55 ± 2.00	8.53 ± 1.43
MPV	5.01 ± 0.19	5.20 ± 0.33	4.97 ± 0.19
PLT	726.50 ± 108.25	696.50 ± 154.38	727.02 ± 127.25
Erythrocytes	8.49 ± 0.37	9.37 ± 1.32	8.30 ± 1.21
RDW	12.50 ± 0.37	12.27 ± 0.39	12.13 ± 0.15

Leukocytes	3.05 ± 0.60	4.25 ± 1.61	2.23 ± 1.77
------------	-------------	-------------	-------------

Effects of treatment with vitamin K2 - MK-7 on vessel wall structure, media thickness, and atherosclerotic plaques size in brachiocephalic artery in older ApoE/LDLR^{-/-} at the stage of advanced atherosclerosis

[0110] As shown in Fig. 11A, in 24-week-old ApoE/LDLR^{-/-} mice treated for eight weeks with vitamin K2 (MK-7), there was a clear-cut effect on vessel wall area (VWA), the parameter representative for media layer thickness of the vascular wall as compared with 24-week-old non-treated ApoE/LDLR^{-/-} mice. The effects of low and high dose of vitamin K2 was similar in magnitude (VWA decreased by about 5% for low and high dose of vitamin K2 - MK-7).

[0111] The plaque size in 24-week-old ApoE/LDLR^{-/-} mice treated with vitamin K2 for eight weeks with vitamin K2 either at low (0.03 mg/kg b.w./day) or at high dose (10 mg/kg b.w./day) was not different as compared with non-treated 24-week-old ApoE/LDLR^{-/-} mice. Internal wall area (IWA, Fig. 11(B)), which is the sum of plaque and lumen areas, decreased only in the middle part of the vessel, in mice treated with lower dose of vitamin K2 (data not shown), but this effect was not visible for entire vessel. Consequently, plaque and lumen area expressed as percent of IWA (Fig. 11(C-D)) did not change in mice treated with either low or high dose of vitamin K2. Lack of the effects of vitamin K2 on atherosclerotic plaque size was compatible with unchanged expression of MAC in atherosclerotic plaques, suggesting similar macrophage contents of the atherosclerotic plaques in treated and non-treated 24-month-old ApoE/LDLR^{-/-} mice (Intensity of MAC-3 staining: 92±28 in untreated mice; 128±26 in mice treated with K2 -

MK-7 in low dose (0.05 mg/kg b.w./day); 139 ± 29 in mice treated with K2 - MK-7 in high dose (10 mg/kg b.w./day)).

Example 3(c): Conclusions

[0112] It was concluded that vitamin K2 (MK-7) improves NO-dependent endothelial function in ApoE/LDLR^{-/-} mice. In particular, the results show that vitamin K2 affords a vasoprotective effect independently of whether endothelial dysfunction was treated with vitamin K2 prior to or concurrently with the occurrence of atherosclerotic plaques in ApoE/LDLR^{-/-} mice, suggesting that vitamin K2 induced an effect on endothelial function that is not linked to a possible anti-atherosclerotic effect of vitamin K2. Furthermore, these results did not confirm any significant effect of vitamin K2 (MK-7) treatment on atherosclerotic plaque size and macrophages content. Vitamin K2-induced improvement of endothelial function was also not linked to changes in activity of coagulation factors, as evidence by unchanged thrombin activity (CAT). It was thus concluded that a low dose of vitamin K2 (MK-7), especially those comparable with effective doses of vitamin K2 recommended for humans to provide benefits for cardiovascular health, may play an important role in the regulation of endothelial function.

[0113] This study shows that a low dose of vitamin K2 (MK-7) may improve endothelial-dependent responses induced by acetylcholine in aorta and induced by flow in femoral aorta. These responses were shown previously to be mediated by endothelial NO in mice. The improvement of endothelial function by treatment with vitamin K2 was confirmed *ex vivo* by EPR measurements in aorta, which showed increased NO production in aorta taken from vitamin K2-treated ApoE/LDLR^{-/-} mice as compared with non-treated animals. The improvement of endothelium dependent vasodilation by

vitamin K2 also correlated with increased nitrite plasma concentration, a reliable marker of endothelial function.

[0114] The treatment with a low dose of vitamin K2 (0.05 mg/kg b.w./day) resulted in barely detectable levels of MK-7 in plasma (detected in two per six mice, amounting to 11.06 nM), suggesting that MK-7 is endowed with pharmacological efficacy to improve endothelial function in the nanomolar range of concentrations. Interestingly, the endothelial effects of vitamin K2 after four weeks of treatment could be accelerated to two weeks of treatment, but not enforced by treatment with higher doses of vitamin K2 (0.5, 5 mg/kg b.w./day), despite higher plasma concentration of MK-7 as well as the parallel increase in plasma concentrations of MK-4 that was achieved by higher doses of vitamin K2 treatment regimens. These results seem compatible with the notion that vitamin K2—MK-7 is converted *in vivo* to vitamin K2—MK-4 via UBIAD1, but whether the endothelial effect reported here was induced directly by MK-7 or by MK-4 after MK-7 metabolism remains to be determined. Nonetheless, this study demonstrates that there is a saturable endothelial mechanism of action of vitamin K2 (MK-7) that was achieved with a relatively low dose of vitamin K2 (MK-7) and low nanomolar range of plasma vitamin K2 concentration.

[0115] The mechanisms involved in vitamin K2—induced improvement of endothelial function was not determined in this study. However, this study confirms that the endothelial effects of vitamin K2 are independent of a coagulation system, as evidenced by unchanged thrombin activity measured based on CAT, a reference method for the quantitative assessment of thrombin generation. The study also excludes the possibility that the improvement of endothelial function by vitamin K2 demonstrated in ApoE/LDLR^{-/-} mice was linked to the inhibition of atherosclerotic plaque formation, as vitamin K2 afforded vasoprotective effects independently of whether endothelial

dysfunction was treated with vitamin K2 prior to or concurrently with the occurrence of atherosclerotic plaques in young and older ApoE/LDLR^{-/-} mice.

[0116] In contrast to the lack of the anti-atherosclerotic effect, vitamin K2 provided a reduced media thickness similar in magnitude for low and high dose of vitamin K2, which could be linked to vitamin K2 dependent carboxylation of matrix Gla-protein (MGP) in smooth muscle cells, a well-described mechanisms of vitamin K2. Hence, a low dose of vitamin K2 was sufficient to improve carboxylation status in smooth muscle cells of the vascular wall in ApoE/LDLR^{-/-} mice. Whether improvement of endothelial NO-dependent function was linked to improved carboxylation status in endothelium, to MGP, or to other vitamin K-dependent proteins (VKPDs) remains to be determined.

[0117] A number of VKPDs were identified in the endothelium, including MGP, an important inhibitor of vascular calcification, Gas6 involved in endothelial survival, and osteocalcin (OC). Based on this study, it is still undetermined which types of VKPDs play a role in the regulation of NO-dependent function. One possibility is that the beneficial effects of vitamin K2 on smooth muscle cells or the anti-inflammatory effects of vitamin K2 also contribute to the improved endothelial function induced by vitamin K2. Furthermore, VKDP-independent mechanisms in endothelium or other cells may also be a possibility.

[0118] In any event, the present study shows that a low dose of vitamin K2, i.e., compatible with effective vasoprotective doses in humans (180-360 µg), improved endothelial function. The data imply that the endothelial effects of vitamin K2 discovered here could contribute to the beneficial effects of vitamin K2 on vascular health. Furthermore, endothelial dysfunction could possibly also be involved in vitamin K insufficiency-associated cardiovascular mortality. This study provides evidence that vitamin K2 treatment improves endothelial dysfunction in ApoE/LDLR^{-/-} mice, a

genetically-driven model of high hypercholesterolemia that represent a distinct endothelial and vascular pathology as compared with aging or menopausal women, studied in human trials, which showed negative results of vitamin K2 treatment on endothelial function. Hence, a possible disease-specific effect of vitamin K2 treatment on endothelial function should be considered.

[0119] In conclusion, the effects of vitamin K2 on endothelial function shown by this study are surprising. Given the fact that the endothelium is involved in most, if not all, disease states (either as a primary determinant of pathophysiology or as a victim of collateral damage), vitamin K2 may be considered a potential vasoprotective agent in various diseases associated with endothelial dysfunction.

What is claimed is:

1. A method for improving cardiovascular function, elasticity, pulse wave velocity or endothelial dysfunction, reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal, comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months.

2. The method according to claim 1, wherein said vitamin K is vitamin K2 and/or vitamin K1.

3. The method according to claim 1, wherein said vitamin K is a combination of vitamin K1 and vitamin K2.

4. The method according to claim 1, wherein said vitamin K is menaquinone -7.

5. The method according to claim 1, wherein said mammal is suffering from a disease selected from the group consisting of CKD, arteriosclerosis, osteoarthritis, inflammation-induced calcification, tumor-induced calcification, skin calcification, and calcifylaxis in end-stage renal disease, and/or wherein said mammal has received a kidney transplant.

6. The method according to claim 5, wherein said arteriosclerosis is Monckeberg's sclerosis, said inflammation-induced calcification is Bechterev's disease, or said skin calcification is pseudo-xanthoma elasticum.

7. The method according to claim 1, wherein said vitamin K is administered for a period of less than 3 months.

8. The method according to claim 7, wherein said vitamin K is administered for a period of less than 6 weeks.

9. The method according to claim 1, wherein said vitamin K is administered in an amount of 150-5000 µg/day.

10. The method according to claim 9, wherein said vitamin K is administered in an amount of 150-500 µg/day.

11. The method according to claim 1, wherein said vitamin K is administered in an amount of 70-14000 µg/week.

12. The method according to claim 10, wherein said vitamin K is administered in an amount of 350-7000 µg/week.

13. The method according to claim 1, wherein said vitamin K is administered in a pharmaceutical or nutritional formulation in a dosage form selected from the group consisting of a tablet, capsule, powder, soft gel, gummy, spray, beverage, food, syrup, and intravenous feed.

14. The method according to claim 13, wherein the pharmaceutical or nutritional formulation further comprises at least one additional pharmaceutically active component.

15. The method according to claim 14, wherein said at least one additional pharmaceutically active component is selected from the group consisting of anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents, beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists.

16. The method according to claim 13, wherein the pharmaceutical or nutritional formulation further comprises at least one additional compound selected from the group consisting of polyphenols, vitamin C, vitamin E, L-Arginine, phytosterol, antihypertensive peptide, soluble fiber, omega-3 fatty acid(s), omega-6 fatty acid(s),

omega-9 fatty acid(s), carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, vitamin B12; and vitamin D.

17. The method according to claim 16, wherein the formulation further comprises vitamin D.

18. The method according to claim 17, wherein the vitamin D is vitamin D3.

19. The method according to claim 1, wherein the daily dosage of vitamin K is from 0.03 to 10 mg/kg body weight.

20. A method of reversing calcification of blood vessels in a mammal suffering from vascular calcification, comprising administering to the mammal an effective amount of vitamin K to reverse calcification of the blood vessel within a period of 2-20 weeks, wherein reversing calcification of a blood vessel includes the removal of preexisting calcium deposits in the blood vessel, on the blood vessel, or a combination thereof.

21. The method according to claim 20, wherein said vascular calcification is a result of Stage 3 CKD, Stage 4 CKD, Stage 5 CKD, and/or hemodialysis.

22. A kit comprising 2-20 weeks of an initial treatment dose of vitamin K and 1 week-36 months of a lower maintenance dose of vitamin K.

23. A method of increasing endothelial nitric oxide production in a subject comprising administering to the subject an effective amount of vitamin K2 for a period of less than 6 months.

24. The method of claim 23, wherein the subject suffers from hypercholesterolemia with atherosclerotic plaques or hypercholesterolemia without atherosclerotic plaques.

25. The method of claim 24, wherein the subject suffers from hypercholesterolemia without atherosclerotic plaques.

26. The method of claim 23, wherein said vitamin K is menaquinone-7.

27. The method of claim 25, wherein said vitamin K is administered in an amount of 180-360 $\mu\text{g}/\text{day}$.




FIG. 1




FIG. 2B

FIG. 2A




FIG. 3B




FIG. 3A




FIG. 4B




FIG. 4A




FIG. 5




FIG. 5 CONT.




FIG. 6



A: FMD-FA




FIG. 7A



B: ACH-AA




FIG. 7B




FIG. 7C




FIG. 7D

9/18




FIG. 7E




FIG. 8A

10/18




FIG. 8B




FIG. 8C

11/18




FIG. 8D




FIG. 8E




FIG. 9

13/18

A: ACH-BCA




FIG. 10A

B: ACH-LCA




FIG. 10B

C: NO₂⁻




FIG. 10C

14/18




FIG. 10D




FIG. 10E

15/18




FIG. 10F




FIG. 10G

16/18




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/25220

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61K 31/122; A61K 31/593; A23L 33/15; A23L 33/155 (2019.01) CPC - A23L 33/15; A23L 33/155; A61K 31/122; A61K 31/593; A23V 2002/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) See Search History Document		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Search History Document		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History Document		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2016/0250160 A1 (NATTOPHARMA AS) 01 September 2016 (01.09.2016) para [0017], [0020]-[0021], [0040]-[0041], [0047], [0050], [0053], [0056], [0060]; claims 11-13	1-21
A	SANO et al. 'Vitamin K2 (menatetrenone) induces iNOS in bovine vascular smooth muscle cells: no relationship between nitric oxide production and gamma-carboxylation.' J Nutr Sci Vitaminol (Tokyo). 1999, Vol.45(6), pages 711-723. Entire Document	1-21
A	WO 2014/022373 A1 (UNITED THERAPEUTICS CORPORATION) 06 February 2014 (06.02.2014) Entire Document	1-21
A	US 2018/0042962 A1 (SUMMIT INNOVATION LABS, LLC) 15 February 2018 (15.02.2018) Entire Document	1-21
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 14 June 2019		Date of mailing of the international search report 04 SEP 2019
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300		Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/25220

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
--Please see attached sheet--

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-21

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/25220

Attachment to Box.No.III:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I: Claims 1-21, directed to a method for improving cardiovascular function, elasticity, pulse wave velocity or endothelial dysfunction, reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal, comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months.

Group II: Claim 22, directed to a kit comprising 2-20 weeks of an initial treatment dose of vitamin K and 1 week-36 months of a lower maintenance dose of vitamin K.

Group III: Claims 23-27, directed to a method of increasing endothelial nitric oxide production in a subject comprising administering to the subject an effective amount of vitamin K2 for a period of less than 6 months.

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I includes the technical feature of reducing arterial stiffness and/or for reversing calcification of a blood vessel in a mammal, not required by Groups II-III.

Group II includes the technical feature of a kit comprising 2-20 weeks of an initial treatment dose of vitamin K and 1 week-36 months of a lower maintenance dose of vitamin K, not required by Groups I and III.

Group III includes the technical feature of a method of increasing endothelial nitric oxide production in a subject, not required by Groups I-II.

Common technical features:

Groups I-III share the technical feature of vitamin K.

Groups I and III further share the technical feature of a method of treating a disorder in a subject comprising administering to the subject an effective amount of vitamin K for a period of less than 6 months.

These shared technical features, however, does not provide a contribution over the prior art, as being anticipated by US 2016/0250160 A1 to Nattopharma As (hereinafter 'Nattopharma'), which discloses a method for reversing calcification of a blood vessel and treating arteriosclerosis in a mammal, comprising administering to the mammal an effective amount of vitamin K (para [0020]-[0021]) for a period of less than 6 months (para [0060], preferred treatment period for the removal of calcification can be at a minimum of 6-12 weeks).

As said method was known in the art at the time of the invention, this cannot be considered a special technical feature, that would otherwise unify the inventions of Groups I-III.

The inventions of Groups I-III, thus, lack unity under PCT Rule 13.